Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?

References

• Nathwani B N, Harris N L, Weisenburger D, Isaacson P G, Piris M A, Berger F, Müller-Hermelink H K, Swerdlow S H. Follicular lymphoma. World Health Organization Classification of Tumors. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, LyonFrance 2001; 162–167
   Google Scholar
• Peterson B A. Current treatment of follicular low-grade lymphomas. Semin Oncol 1999; 5: 2–11
   Google Scholar
• Simon R, Durrleman S, Hoppe R T, Bonadonna G, Bloomfield C D, Rudders R A, et al. The non-Hodgkin lymphoma pathologic classification project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med 1988; 109: 939–945
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Hermans J, Krol A D, van Groningen K, Kluin P M, Kluin-Nelemans J C, Kramer M H, et al. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460–1463
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Montserrat E, Bosch F, Terol M J, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–1348
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Plancarte F, Lopez-Guillermo A, Arenillas L, Montoto S, Gine E, Muntanola A, et al. Follicular lymphoma in early stages: high risk of relapse and usefulness of the follicular lymphoma international prognostic index to predict the outcome of patients. Eur J Haematol 2006; 76: 58–63
   PubMed Web of Science ®Google Scholar
• Montoto S, Lopez-Guillermo A, Altes A, Perea G, Ferrer A, Camos M, et al. Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004; 15: 1484–1489
   PubMed Web of Science ®Google Scholar
• Perea G, Altes A, Montoto S, Lopez-Guillermo A, Domingo-Domenech E, Fernandez-Sevilla A, et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005; 16: 1508–1513
   PubMed Web of Science ®Google Scholar
• Arcaini L, Colombo N, Passamonti F, Burcheri S, Orlandi E, Brusamolino E, et al. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res 2006; 30: 277–282
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The follicular lymphoma international prognostic index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504–1508
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN), The complete library of practice guidelines in oncology (online). Version 2006. Available from: www.nccn.org
   Google Scholar
• Hans C, Weisenburger D, Vose J, Hock L, Lynch J, Aoun P, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363–2367
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger L R, Yunis J, Nowell P C, Croce C M. Cloning of the chromosome breakpoint of neoplastic B cell with the t(14;18) chromosome translocation. Science 1984; 226: 1097–1099
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Cossman J, Jaffe E, Croce C M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440–1443
   PubMed Web of Science ®Google Scholar
• Yunis J J, Oken M M, Kaplan M E, Ensrud K M, Howe R R, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982; 307: 1231–1236
   PubMed Web of Science ®Google Scholar
• Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 1995; 13: 513–543
   PubMed Web of Science ®Google Scholar
• Oltvai Z N, Milliman C L, Korsmeyer S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Vaux D L, Cory S, Adams J M. Bcl-2 gene promotes haematopoietic cell survival and cooperateswith c-myc to immortalize pre-B cells. Nature 1988; 335: 440–442
   PubMed Web of Science ®Google Scholar
• Arber D A. Molecular diagnostic approach to non-Hodgkin's lymphoma. J Mol Diag 2000; 2: 178–190
   PubMed Web of Science ®Google Scholar
• López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez M A, et al. Correlation of bcl-2 rearrangemnt with clinical characteristics and outcome in indolent follicular lymphomas. Blood 1999; 93: 3081–3087
   PubMed Web of Science ®Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 21: 2159–2169
   Web of Science ®Google Scholar
• Harjunpaa A, Taskinen M, Nykter M, Karjalainen-Lindsberg M L, Nyman H, Monni O, et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006; 135: 33–42
   PubMed Web of Science ®Google Scholar
• Perea G, Altés A, Montoto S, López-Guillermo A, Bosch F, Jiménez M, et al. International and Italian prognostic indices in follicular lymphoma. Haematologica 2003; 88: 700–704
   PubMed Web of Science ®Google Scholar
• Perea G, Altés A, Monoto S, López-Guillermo A, Domingo-Doménech E, Fernández-Sevilla A, et al. Prognostic indexes in follicular lymphoma: a comparison of different prgnostic systems. Ann Oncol 2005; 16: 1508–1513
   PubMed Web of Science ®Google Scholar
• van Oers M H, Klasa R, Marcus R E, Wolf M, Kimby E, Gascoyne R D, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 2006; 108: 3295–3301
   PubMed Web of Science ®Google Scholar